Related references
Note: Only part of the references are listed.Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab
Bosse Jessen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis
Leonie C. S. De Vries et al.
JOURNAL OF CROHNS & COLITIS (2021)
Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus
Thomas Greuter et al.
DIGESTION (2020)
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab
Brigida Barberio et al.
INFLAMMATORY BOWEL DISEASES (2020)
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease
Parambir S. Dulai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Parambir S. Dulai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Modulation of sphingosine-1-phosphate in ulcerative colitis
Marjorie Argollo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
Aleksejs Sazonovs et al.
GASTROENTEROLOGY (2020)
Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease
N. S. Ding et al.
JOURNAL OF CROHNS & COLITIS (2020)
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2020)
Crohn's disease
Giulia Roda et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis
Ferdinando D'Amico et al.
JOURNAL OF CROHNS & COLITIS (2020)
Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease
Clara Caenepeel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ulcerative colitis
Taku Kobayashi et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
Ferdinando D'Amico et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Pathophysiology of Inflammatory Bowel Diseases
John T. Chang
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Ahmed Almradi et al.
BIODRUGS (2020)
Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials
Ole Haagen Nielsen et al.
ECLINICALMEDICINE (2020)
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies
Konstantinos H. Katsanos et al.
CLINICAL IMMUNOLOGY (2019)
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Belen Beltran et al.
DIGESTIVE DISEASES (2019)
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh et al.
DRUG SAFETY (2019)
Methotrexate for inflammatory bowel disease: time for reconsideration
Ole Haagen Nielsen et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease
Lyssia Belarif et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Genetic Studies of Inflammatory Bowel Disease-Focusing on Asian Patients
Sung Chul Park et al.
CELLS (2019)
Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases
Konrad Aden et al.
GASTROENTEROLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
Sare Verstockt et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
Suhail Nurbhai et al.
SCIENTIFIC REPORTS (2019)
Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease
Bram Verstockt et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease
Fabio Salvatore Macaluso et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2019)
A Genome-wide Association Study Identifying RAP1A as a Novel Susceptibility Gene for Crohn's Disease in Japanese Individuals
Yoichi Kakuta et al.
JOURNAL OF CROHNS & COLITIS (2019)
Microbial network disturbances in relapsing refractory Crohn's disease
Bahtiyar Yilmaz et al.
NATURE MEDICINE (2019)
Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison
Ehsan Motaghi et al.
PHARMACOLOGICAL RESEARCH (2019)
Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study
Lauren Beswick et al.
JOURNAL OF CROHNS & COLITIS (2018)
Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials
Siddharth Singh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients
Matthew K. Doherty et al.
MBIO (2018)
The value of Fecal Markers in Predicting Relapse in inflammatory Bowel Diseases
Bianca J. Galgut et al.
FRONTIERS IN PEDIATRICS (2018)
Targeting JAK-STAT signal transduction in IBD
Christoffer Soendergaard et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
L. Angelison et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Marisa Iborra et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Uni Wong et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Alicaforsen for the treatment of inflammatory bowel disease
Vipul Jairath et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
JAK inhibition in inflammatory bowel disease
Pablo Olivera et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panes et al.
GUT (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Nathaniel R. West et al.
NATURE MEDICINE (2017)
Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease
Ole Haagen Nielsen et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology
Karen Dubois-Camacho et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Ping Li et al.
FRONTIERS IN PHARMACOLOGY (2017)
Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis
Yu Nishida et al.
PLOS ONE (2017)
Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis
Elham A. Hassan et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2017)
Modulation of sphingosine-1-phosphate in inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
AUTOIMMUNITY REVIEWS (2017)
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF- naive Crohn's disease
N. Narula et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases
S. Bek et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Silvio Danese et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2016)
The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study
Joao Santos-Antunes et al.
INFLAMMATORY BOWEL DISEASES (2016)
Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy
Valeria Caneparo et al.
INFLAMMATORY BOWEL DISEASES (2016)
Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
Maria K. Magnusson et al.
JOURNAL OF CROHNS & COLITIS (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
Caroline Meyer Olesen et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Corticosteroids Mechanisms of Action in Health and Disease
Sivapriya Ramamoorthy et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2016)
Prediction of clinical and endoscopic responses to anti-tumor necrosis factor- antibodies in ulcerative colitis
Yukihiro Morita et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease
Penelope Pelczar et al.
SCIENCE (2016)
Antibody markers in the diagnosis of inflammatory bowel disease
Keiichi Mitsuyama et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy
Angela C. Baird et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
Chang Hwan Choi et al.
YONSEI MEDICAL JOURNAL (2016)
Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease
Kelly A. Shaw et al.
GENOME MEDICINE (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation
Kaija-Leena Kolho et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
Naoki Yoshimura et al.
GASTROENTEROLOGY (2015)
Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis
Apoorva K. Chandar et al.
INFLAMMATORY BOWEL DISEASES (2015)
Epidemiology and risk factors for IBD
Ashwin N. Ananthakrishnan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD
Douglas L. Nguyen et al.
SOUTHERN MEDICAL JOURNAL (2015)
Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug
Cristiana Perrotta et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2015)
Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics
Kine Marita Knudsen Sand et al.
FRONTIERS IN IMMUNOLOGY (2015)
Genome-wide association scan in north Indians reveals three novel HLA-independent risk loci for ulcerative colitis
Garima Juyal et al.
GUT (2015)
Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis
David Kevans et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease
Jun Miyoshi et al.
DIGESTION (2014)
Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations
Suk-Kyun Yang et al.
GUT (2014)
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
Kathleen Machiels et al.
GUT (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease
Sylvie Rajca et al.
INFLAMMATORY BOWEL DISEASES (2014)
An update on the biology of sphingosine 1-phosphate receptors
Victoria A. Blaho et al.
JOURNAL OF LIPID RESEARCH (2014)
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
Raja Atreya et al.
NATURE MEDICINE (2014)
Inflammatory bowel disease: Pathogenesis
Yi-Zhen Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Inflammatory bowel disease: clinical aspects and treatments
Marc Fakhoury et al.
JOURNAL OF INFLAMMATION RESEARCH (2014)
Smoking does influence disease behaviour and impacts the need for therapy in Crohns disease in the biologic era
T. Nunes et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents
Roslyn Kemp et al.
BIODRUGS (2013)
Influence of polymorphisms and TNF and IL1 beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis
Diana Lacruz-Guzman et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A Genome-Wide Association Study Identifies 2 Susceptibility Loci for Crohn's Disease in a Japanese Population
Keiko Yamazaki et al.
GASTROENTEROLOGY (2013)
Tumor necrosis factor-alpha antagonists: Side effects and their management
Sunil Dogra et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2013)
Genome-Wide Association Study of Ulcerative Colitis in Koreans Suggests Extensive Overlapping of Genetic Susceptibility With Caucasians
Suk-Kyun Yang et al.
INFLAMMATORY BOWEL DISEASES (2013)
Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer
Carmine Stolfi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Recent Advances Using Immunomodulators for Inflammatory Bowel Disease
Ole Haagen Nielsen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease
Anders Dige et al.
JOURNAL OF CROHNS & COLITIS (2013)
Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study
Kang-Moon Lee et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Ole Haagen Nielsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis
Qiang Tong et al.
PHARMACOGENOMICS (2013)
A clinical review of recent findings in the epidemiology of inflammatory bowel disease
Millie Long et al.
Clinical Epidemiology (2013)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Epidemiology and clinical course of Crohn's disease: Results from observational studies
Oistein Hovde et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives
Marie Joossens et al.
GUT (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease
Sara Bogaert et al.
BMC IMMUNOLOGY (2010)
Mesalazine in inflammatory bowel disease: A trendy topic once again?
Marietta Iacucci et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
David Shealy et al.
MABS (2010)
Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
Amir Klein et al.
PHARMACEUTICALS (2010)
Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis
G. T. Ho et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis
Trine Olsen et al.
CYTOKINE (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Effects of Light Smoking Consumption on the Clinical Course of Crohn's Disease
Philippe Seksik et al.
INFLAMMATORY BOWEL DISEASES (2009)
A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population
Kouichi Asano et al.
NATURE GENETICS (2009)
Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Microbial influences in inflammatory bowel diseases
R. Balfour Sartor
GASTROENTEROLOGY (2008)
Long-term outcome after infliximab for refractory ulcerative colitis
Marc Ferrante et al.
JOURNAL OF CROHNS & COLITIS (2008)
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
Tibor Hlavaty et al.
INFLAMMATORY BOWEL DISEASES (2007)
Predictors of early response to infliximab in patients with ulcerative colitis
Marc Ferrante et al.
INFLAMMATORY BOWEL DISEASES (2007)
Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis
S. Joossens et al.
GUT (2006)
Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease
George E. Reese et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis
RB Sartor
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2006)
New genes in inflammatory bowel disease: lessons for complex diseases?
DR Gaya et al.
LANCET (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Review article: smoking cessation as primary therapy to modify the course of Crohn's disease
GJ Johnson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study
SL Jowett et al.
GUT (2004)
Inflammatory bowel disease: the role of environmental factors
S Danese et al.
AUTOIMMUNITY REVIEWS (2004)
Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice
RC Burns et al.
GASTROENTEROLOGY (2001)
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine
OH Nielsen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
JP Hugot et al.
NATURE (2001)
Share Paper
